Baseline self-reported supplement category use and two-visit difference in lipoprotein(a): an observational analysis in UK Biobank.

What Was Tested

The paper reports a study of Copper (Supplement), published as an observational study.

The researchers aimed to investigate associations between baseline self-reported supplement-category use and two-visit difference in Lp(a), and to explore whether these associations differed by Lp(a) genetic risk.

Why It Was Studied

Circulating Lp(a) is largely genetically determined, but repeated measurements indicate that Lp(a) concentrations may differ within individuals over time.

Who Took Part

According to the abstract, 12,109 participants were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

The researchers included 12,109 UK Biobank participants with Lp(a) measured at baseline and at the first repeat assessment.

Self-reported use of common supplement categories (vitamins A, B, C, D, E, folate, and multi-vitamins) was assessed by questionnaire.

How the Study Was Run

The primary outcome was the continuous two-visit difference in log10[Lp(a)], defined as log10[repeat-assessment Lp(a)] minus log10[baseline Lp(a)].

The primary analysis used core behavioral/sociodemographic-adjusted multivariable linear regression.

Threshold-category and genetic-risk analyses were secondary and exploratory.

What Was Measured

Circulating Lp(a) is largely genetically determined, but repeated measurements indicate that Lp(a) concentrations may differ within individuals over time.

PubMed files the paper under topics including Lipoprotein(a), Dietary Supplements, United Kingdom, Self Report, Biological Specimen Banks, UK Biobank and Vitamins.

Author keywords: genetic risk, observational study and vitamin supplements.

What This Means in Plain Language

This is an observational study of Copper (Supplement) in 12,109 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Lipids in health and disease), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.